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The epidermal growth factor receptor (EGFR/HER1) is a
member of the erbB family of receptor tyrosine kinase
proteins, which also includes HER2, HER3, and HER4.
EGFR is almost universally expressed in squamous cell
carcinoma of head and neck (SCCHN), and high levels
of expression have been correlated with a poor clinical
prognosis [1]. Cetuximab, an IgG1 monoclonal antibody
against EGFR, has demonstrated improved survival and
disease control when used in combination with radiation
therapy for the treatment of locally advanced SCCHN,
and in combination with platinum-based chemotherapy
in recurrent or metastatic SCCHN [2-4]. Additionally,
single-agent cetuximab is active and provides good dis-
ease control rate and duration in platinum-refractory
SCCHN [5]. Comparison of cetuximab versus cisplatin
concurrently with radiotherapy is under investigation in
patients with human papillomavirus-associated orophar-
yngeal cancer, who have better prognosis and may bene-
fit from less toxic treatment [6].
Overexpression of HER2 in gastric cancer results in
aggressive clinical course and poor prognosis [7]. Trastu-
zumab, a monoclonal antibody against HER2, exhibits
antitumor activity in HER2 overexpressed gastric cancer
cells, and enhances effects of chemotherapy in gastric
cancer xenograft overexpressing HER2 [8]. The ToGA
study screened about 3,800 patients with advanced gastric
cancer from 24 countries, and HER2 overexpression was
detected in 22% [9]. Higher rates of HER2 overexpression
occurred in intestinal and proximal or gastroesophageal
junction cancers than in diffuse or distal gastric cancers.
In TOGA study, 584 patients with HER2 overexpression
were randomized to receive fluoropyrimidine and cisplatin
treatment with or without trastuzumab. Patients who
received trastuzumab plus chemotherapy achieved longer
overall survival (13.8 months vs. 11.1 months, P= 0.0046),
longer progression-free survival (6.7 months vs. 5.5
months, P=0.0002), and higher response rates (47% vs.
35%, P=0.0017) than those who received chemotherapy
alone. Complete response was noted in 5.4% of patients
receiving trastuzumab plus chemotherapy vs. 2.4% in che-
motherapy alone. There were no significant differences in
the toxicities between these two groups. This study has
established a new paradigm using trastuzumab in combi-
nation with chemotherapy in patients with advanced gas-
tric cancer overexpressing HER2.
Neoadjuvant treatment is a standard of care for locally
advanced esophageal and gastric cancer. We have pre-
viously reported a case of pathological complete
response after neoadjuvant chemotherapy with trastuzu-
mab-containing regimen in HER2-overexpressing gastric
cancer [10]. Incorporating trastuzumab as a part of
neoadjuvant therapy in esophageal and gastric adenocar-
cinoma overexpressing HER2 is currently under active
investigation. Radiation Therapy Oncology Group is
conducting a phase III neoadjuvant study in patients
with HER2-overexpressing esophageal adenocarcinoma
to determine if trastuzumab increases disease-free survi-
val when added to chemoradiotherapy [11]. Other stu-
dies conducted in Europe are adding trastuzumab to
oxaliplatin-based regimen as perioperative chemotherapy
for HER2-overexpressing esophagogastric or gastric ade-
nocarcinoma, and looking for improvement of patholo-
gical complete response and disease-free survival [12,13].
Pertuzumab is a monoclonal antibody interfering with
HER2 dimerization with other HER receptors such as
EGFR, HER3 and HER4. Pertuzumab and trastuzumab
bind to HER2 at different sites, and combination of both
antibodies leads to stronger inhibition of erbB signaling
and greater therapeutic efficacy when combined with doc-
etaxel in breast cancer [14]. Combination of pertuzumab
and trastuzumab with platinum-based chemotherapy is
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